# Randomized, Double-blind, Placebo-controlled Study to Assess Fatigue in Patients With ACD Due to RA Receiving PROCRIT

> **NCT00236678** · PHASE2 · TERMINATED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 29 (actual)

## Conditions studied

- Anemia
- Rheumatoid Arthritis

## Interventions

- **DRUG:** Epoetin alfa

## Key facts

- **NCT ID:** NCT00236678
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-07
- **Primary completion:** —
- **Final completion:** 2006-01
- **Target enrollment:** 29 (ACTUAL)
- **Why stopped:** This study was terminated due to slow enrollment, despite protocol amendments to change the entrance criteria.
- **Last updated:** 2011-06-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00236678

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00236678, "Randomized, Double-blind, Placebo-controlled Study to Assess Fatigue in Patients With ACD Due to RA Receiving PROCRIT". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT00236678. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*